Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of
these deaths occur suddenly where treatment is impossible, the best treatment is prevention.
With this grant, researchers in Missouri, New York, Utah, Illinois, and Texas are developing
strategies to improve the safety and effectiveness of clot prevention by customizing a
popular blood thinner (warfarin) to each person's genetic and clinical profile. They
hypothesize that the use of genetics to guide warfarin therapy will reduce the risk of venous
thromboembolism (VTE) postoperatively. They further hypothesize that using a target
international normalized ratio (INR) of 1.8 is non-inferior to using a target INR of 2.5 in
VTE prevention.
Phase:
Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Hospital for Special Surgery, New York Intermountain Health Care, Inc. National Heart, Lung, and Blood Institute (NHLBI) Rush University Medical Center University of Texas Southwestern Medical Center University of Utah